We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Radiofrequency Energy Systems Treat Reflux and Incontinence

By HospiMedica International staff writers
Posted on 23 Nov 2010
Innovative systems for the treatment of gastroesophageal reflux disease (GERD) and bowel control disorder (BCD) include a streamlined user interface and significant improvements in ease of use.

The Stretta system for the treatment of GERD is based on an endoscopically guided, minimally invasive outpatient procedure performed in 60 minutes or less. More...
Using the Stretta Catheter, precise and safe delivery of radiofrequency (RF) energy to the lower esophageal sphincter (LES), muscle, and gastric cardia is achieved. As the treated areas heal, the barrier function of the LES is augmented, reducing the frequency and severity of reflux events. There is no hospital stay involved with the Stretta procedure and patients are typically able to return to normal activities the following day.

The Secca system for BCD involves similar delivery of RF energy to the muscles of the anal canal, which results in a change in tissue compliance and corresponding improvement in incontinence symptoms. The outpatient procedure takes approximately 45 minutes, and it is performed in an endoscopy suite or ambulatory surgery unit with the patient under general anesthesia (GA) or conscious sedation. Patients return home approximately one to two hours after the procedure, and typically resume normal activities within several days. The Stretta and Secca systems are products of Mederi Therapeutics (Greenwich, CT, USA), and have received the European Community (CE) marking of approval.

"As the only endoluminal therapies for GERD and BCD, the interest and demand for these novel technologies is extremely high,” said Will Rutan, CEO and president of Mederi Therapeutics. "It was exciting to witness the overwhelming response to Stretta and Secca, resulting in numerous requests to purchase Mederi products.”

Both ultra-minimally invasive technologies are small, light, and highly portable, and are based on the same operating procedure. The physician positions the device and deploys the needle electrodes, resulting in RF energy streamed in a controlled manner to the tissue surrounding the needle electrodes; the treatment sequence is repeated to create well-defined thermal lesions in the muscles; as a result, transient muscle relaxations are reduced by the disruption of nerve pathways within the area. Over time, the treated areas resorb and the tissue remodels, further increasing resistance to sudden relaxation.

Related Links:
Mederi Therapeutics


Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Bipolar Coagulation Generator
Aesculap
Electric Bed
DIXION Intensive Care Bed
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.